Vimarsana
Biggest News Aggregation in the World

Page 2 - Session Time News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Session Time. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Session Time Today - Breaking & Trending Today

[LIVE@STREAMs!]]**F1 Italian Grand Prix LIVE Broadcast - Vimarsana News

[LIVE@STREAMs!]]**F1 Italian Grand Prix LIVE Broadcast

Watch F1 via live stream or on TV: dates and times for the 2023 Italian Grand Prix from Monza, including qualifying and the grand prix.

EISAI TO PRESENT THE LATEST ALZHEIMER'S DISEASE PIPELINE AND RESEARCH, INCLUDING LECANEMAB AND ANTI-MTBR TAU ANTIBODY E2814, AT THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2023 - Vimarsana News

EISAI TO PRESENT THE LATEST ALZHEIMER'S DISEASE PIPELINE AND RESEARCH, INCLUDING LECANEMAB AND ANTI-MTBR TAU ANTIBODY E2814, AT THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2023

/PRNewswire/ -- Eisai Co. Ltd (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the company will present the latest findings on its...

Viracta Therapeutics Announces Preliminary Dose-Ranging - Vimarsana News

Viracta Therapeutics Announces Preliminary Dose-Ranging

Data from first two dose levels of Nana-val in patients with EBV+ recurrent/metastatic nasopharyngeal carcinoma support continued dose escalation to...

ADC Therapeutics SA: ADC Therapeutics Announces Abstracts Accepted for Presentation at the 64th ASH Annual Meeting - Vimarsana News

ADC Therapeutics SA: ADC Therapeutics Announces Abstracts Accepted for Presentation at the 64th ASH Annual Meeting

Multiple presentations will highlight the clinical utility of ZYNLONTA (loncastuximab tesirine-lpyl) in DLBCL and Cami (camidanlumab tesirine) in Hodgkin lymphoma ADC Therapeutics SA (NYSE: ADCT)

Data from Incyte's Robust and Progressing Oncology Portfolio to be Presented at 2022 EHA Annual Meeting - Vimarsana News

Data from Incyte's Robust and Progressing Oncology Portfolio to be Presented at 2022 EHA Annual Meeting

Incyte (Nasdaq:INCY) today announced that multiple abstracts featuring data from its oncology portfolio will be presented at the upcoming European Hematology Association 2022 (EHA2022) Congress (June